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Summary
Background Artemisinin-based combination therapies (ACTs) are the most effective treatment for uncomplicated 
Plasmodium falciparum malaria infection. A commonly used indicator for monitoring and assessing progress in 
coverage of malaria treatment is the proportion of children younger than 5 years with reported fever in the previous 
14 days who have received an ACT. We propose an improved indicator that incorporates parasite infection status (as 
assessed by a rapid diagnostic test [RDT]), which is available in recent household surveys. In this study we estimated 
the annual proportion of children younger than 5 years with fever and a positive RDT in Africa who received an ACT 
in 2003–15.
Methods Our modelling study used cross-sectional data on treatment for fever and RDT status for children younger 
than 5 years compiled from all nationally available representative household surveys (the Malaria Indicator Surveys, 
Demographic and Health Surveys, and Multiple Indicator Cluster Surveys) across sub-Saharan Africa between 2003 
and 2015. Estimates for the proportion of children younger than 5 years with a fever within the previous 14 days and 
P falciparum infection assessed by RDT who received an ACT were incorporated in a generalised additive mixed 
model, including data on ACT distributions, to estimate coverage across all countries and time periods. We did 
random effects meta-analyses to examine individual, household, and community effects associated with ACT coverage.
Findings We obtained data on 201 704 children younger than 5 years from 103 surveys (22 MIS, 61 DHS, and 20 MICS) 
across 33 countries. RDT results were available for 40 of these surveys including 40 261 (20%) children, and we 
predicted RDT status for the remaining 161 443 (80%) children. Our results showed that ACT coverage in children 
younger than 5 years with a fever and P falciparum infection increased across sub-Saharan Africa in 2003–15, but even 
in 2015, only 19·7% (95% CI 15·6–24·8) of children younger than 5 years with a fever and P falciparum infection 
received an ACT. In meta-analyses, children younger than 5 years were more likely to receive an ACT for fever and 
P falciparum infection if they lived in an urban area (vs rural area; odds ratio [OR] 1·18, 95% CI 1·06–1·31), had 
household wealth above the national median (vs wealth below the median; OR 1·26, 1·16–1·39), had a caregiver with 
any education (vs no education; OR 1·31, 1·22–1·41), had a household insecticide-treated net (ITN; vs no ITN; OR 1·21, 
1·13–1·29), were older than 2 years (vs ≤2 years; OR 1·09, 1·01–1·17), or lived in an area with a higher mean 
P falciparum prevalence in children aged 2–10 years (OR 1·12, 1·02–1·23). In the subgroup of children for whom 
treatment was sought, those who sought treatment in the public sector were more likely to receive an ACT (vs the 
private sector; OR 3·18, 2·67–3·78).
Interpretation Despite progress during the 2003–15 malaria programme, ACT treatment for children with malaria 
remains unacceptably low. More work is needed at the country level to understand how health-care access, service 
delivery, and ACT supply might be improved to ensure appropriate treatment for all children with malaria.
Funding US President’s Malaria Initiative and Medicines for Malaria Venture.
Copyright © The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Nearly half of the world’s population is at risk of 
Plasmodium falciparum malaria,1 the most lethal species 
of malaria parasite. In 2015, P falciparum infections led 
to an estimated 187 million cases and 398 000 deaths 
across sub-Saharan Africa.1,2 Fortunately, P falciparum 
infection is treatable with available antimalarials. 
Following the emergence of widespread drug resistance 
to chloroquine and sulfadoxine–pyrimethamine,3 
artemisinin-based combination therapies (ACTs) were 
introduced as a highly effective treatment for 
uncomplicated malaria (both for P falciparum and 
Plasmodium vivax infections), preventing progression to 
severe disease and death.4,5
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The WHO-recommended first-line treatment for 
uncomplicated P falciparum malaria in nearly all endemic 
countries is an ACT.6 Funding for procuring ACTs has 
greatly increased and they are now widely available from 
multiple manufacturers and in many formulations. 
Between 2003 and 2007, nearly all countries in Africa 
changed their treatment policy to ACTs as the first-line 
treatment of uncomplicated malaria, and since then, a 
major rise has been seen in global ACT procurement and 
distribution.7
To date, one of the most commonly used indicators for 
monitoring global progress in the treatment of malaria 
has been the proportion of children with a fever in the 
previous 2 weeks that received an effective antimalarial, as 
measured by mother’s recall during nationally 
representative household surveys.8 Although this measure 
is available from household surveys and gives some 
indication of the extent of malaria treatment, it has several 
notable limitations. Most crucially, the proportion of 
children who have had an antimalarial does not indicate 
whether the fever was associated with an actual malaria 
parasite infection. Even if a country achieves a reasonably 
high level of treatment of fevers with an effective 
antimalarial, which for the past decade has been an ACT, 
this measure can be highly misleading because it includes 
inappropriate treatment of non-malarial fevers. Although 
an increasing proportion of patients with suspected 
malaria undergo malaria diagnostic testing, in many 
settings across Africa, treatment still relies on clinical 
diagnosis of malaria on the basis of fever without 
laboratory confirmation. Another limitation of this 
approach is that household surveys are done intermittently, 
or not at all in some countries. Because of changes in the 
availability of drugs or clinical practice, treatment coverage 
might vary in the years between surveys. Providing an 
estimate of treatment coverage in non-survey years might 
help programmes better assess their progress and respond 
in a more timely manner to deficiencies in service delivery.
A more useful indicator for measuring progress in 
combating malaria is the proportion of children with a 
fever plus a P falciparum infection in the previous 2 weeks 
who received an ACT. Since 2006, many national household 
surveys in Africa have added in assessments using rapid 
diagnostic tests (RDTs) that detect the P falciparum parasite 
histidine-rich protein 2 (hrp2), which can be used as a 
measure of P falciparum parasite prevalence. Because hrp2 
circulates for up to several weeks after P falciparum has 
been cleared,9,10 RDTs can detect infections up to 42 days 
after parasite clearance, with almost all infections detected 
up to 7 days, and about 80% detected up to 14 days after 
parasite clearance.11 Because of this property, hrp2 RDTs 
done at the time of the survey provide an approximate 
measure of 2-week infection period prevalence12 that 
overlays effectively with the reported history of fever and 
malaria treatment in the surveys.
In this study, our objective was to estimate the proportion 
of children younger than 5 years with a recent fever and a 
positive P falciparum RDT who were treated with an ACT 
from 2003 to 2015 in all P falciparum-endemic countries in 
Africa, as measured by national household surveys.
Methods
Study design and data sources
This study was a modelling analysis that used cross-
sectional data obtained from nationally representative 
household surveys. We used the STROBE guidelines in 
Research in context
Evidence before this study
A wealth of nationally representative household survey data 
has become available over the past 10 years to help malaria 
programmes monitor and assess their progress in achieving 
high population coverage of effective interventions, including 
case management with effective diagnostic tools and 
treatment with antimalarials, which over the past decade have 
been artemisinin-based combination therapies (ACTs). 
Achieving a high rate of treatment with ACTs for all children 
with malaria is crucial to preventing severe disease and death. 
To gather evidence on progress in ACT treatment coverage 
before this study, we searched PubMed with the keywords 
“artemisinin combination therapy” and “malaria case 
management” in combination with “coverage”. We applied no 
language or publication date restrictions. The date of our last 
search was March 10, 2016. Several studies have used 
household survey data collected in single countries to examine 
ACT treatment rates for children with fever, and three recent 
studies have examined ACT treatment rates for children with 
fever for several countries across Africa using national 
household survey data. We found no studies that examined 
coverage of ACT treatment at the continental level over time 
for children with fever, or that examined ACT coverage for 
children with a Plasmodium falciparum infection from 
household survey data.
Added value of this study
To our knowledge, this is the first study to estimate the 
coverage of ACT treatment for children younger than 5 years 
with fever and a P falciparum infection across sub-Saharan 
Africa over time.
Implications of all the available evidence
Our results show that while coverage of ACT treatment has 
increased, it remains unacceptably low, and the likelihood of 
treatment is lower in rural, poorer populations and those who 
receive care through the private sector. Increased efforts are 
needed by malaria programmes and policy makers to ensure 
that treatments are available to patients who most need them, 
and inappropriate treatment of those without malaria infection 
is kept to a minimum.
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the reporting of this study,13 and a checklist is included in 
the appendix pp 38–39.
We included data from publicly available national 
population-based surveys that measured the 2-week 
history of fever and malaria treatment for children 
younger than 5 years, categorised by type of antimalarial 
received. These surveys were the Malaria Indicator 
Surveys (MIS), Demographic and Health Surveys (DHS), 
and Multiple Indicator Cluster Surveys (MICS) done in 
2003–15. The sampling methods for these surveys have 
been described in detail elsewhere.14 In addition to a 
questionnaire intended to measure household wealth, 
household insecticide-treated net (ITN) ownership, and 
caregiver education level, these surveys also ascertain 
data on occurrence of and care for fever, cough, and 
diarrhoea from all caregivers of children younger than 
5 years, and the MIS and some DHS measure 
P falciparum infection status of children younger than 
5 years in sampled households.
We obtained data on the number of ACTs and other 
antimalarials distributed by national programmes per 
year in 2003–15 from the WHO World Malaria Report.7 
We standardised ACT distributions by dividing by the 
total population at risk per country (using estimates from 
the Malaria Atlas Project [MAP]) to produce ACT 
availability per capita (ACTcap), and calculated annual 
population estimates using growth rates derived from 
the UN Population Prospects database. We also obtained 
annual estimates of P falciparum prevalence in children 
aged 2–10 years (PfPR2–10) from MAP that we extracted at 
the latitude and longitude for each survey cluster. We 
excluded countries that had a national mean PfPR2–10 of 
less than 2% in any year, because the prevalences of 
P falciparum and fever were too low to provide reasonable 
sample sizes in these countries.
Definitions
We defined coverage of ACT treatment for children 
younger than 5 years with fever and a P falciparum 
infection as the proportion of children younger than 
5 years with a fever in the previous 2 weeks and a positive 
RDT test at the time of survey who were reported as 
receiving an ACT. We defined household ITN ownership 
as the presence of at least one ITN in the household at 
the time of the survey, and determined household wealth 
using principal components analysis of household 
assets.15 Education level of the child’s caregiver was 
categorised as any or none. Endemicity level was defined 
for each survey cluster as hypoendemic (<10% PfPR2–10), 
mesoendemic (10–50%), and hyperendemic or holo-
endemic (>50%) on the basis of the mean PfPR2–10 at each 
cluster. Season was determined by whether the median 
survey date was during the rainy or dry season. We 
classified the source of treatment for fever as public if 
treatment was sought from any governmental source, 
and as private if treatment was sought from any non-
governmental source, including informal care. To 
examine regional trends, we classified countries on the 
basis of UN Africa subregion (western, central, and 
eastern), and whether or not they received funding 
through the Affordable Medicines Facility malaria 
(AMFm) scheme.
Statistical analysis
In most surveys except the MIS and some recent DHS, 
parasite prevalence by RDT was not measured. Given the 
paucity of data available to create a complete time series 
measuring ACT treatment for children younger than 
5 years with fever and a P falciparum infection across 
countries from 2003–15, we used a three-step modelling 
approach to predict coverage for surveys without RDT 
measurement and used approximate Bayesian time 
series methods that included ACT distribution data to 
impute data for countries and years with missing data. 
We used random effects meta-analyses of the survey 
datasets to assess associations between individual-level 
ACT treatment and various predictors. All analyses were 
done using R 3.2.3 and Stata 13.1.
National-level and continent-level coverage estimates
First, for national surveys without RDTs (most DHS and 
all MICS), we modelled the propensity of children with a 
fever to be RDT positive on the basis of a set of predictive 
factors. We used all available survey datasets with RDT 
results at the time of survey to parameterise a logistic 
regression model to predict malaria parasite infection in 
febrile children. In the regression model, we included the 
child’s age, household wealth quintile, household ITN 
ownership, urban or rural status, season (rainy or dry), and 
malaria transmission intensity for the survey year, 
measured by logit-transformed PfPR2–10. To account for 
uncertainty and obtain predictions of RDT status in all 
children with a fever from the compiled surveys, we 
sampled values of logit-transformed PfPR2–10 at each survey 
location and time, and used the coefficients estimated 
from logistic model estimations to produce predicted 
probabilities of RDT status for each child. We then 
sampled values using the binomial distribution to produce 
binary predictions for each child (appendix p 4). For each 
of these child-level predictions we then calculated the 
national survey-weighted proportion of children younger 
than 5 years with a fever and positive RDT test (as 
measured, or predicted if not measured) who received an 
ACT for each survey.
At the last step, we imputed ACT coverage values for 
each country and year with no survey dataset available 
using a generalised additive mixed model (GAMM) that 
incorporated the relationship between ACT coverage and 
ACTcap across countries. National annual ACT coverage 
was modelled as a function of time, country, UN Africa 
subregion, and ACTcap. Gaps in the ACT coverage time 
series for each country were filled on the basis of posterior 
means of the model’s fixed effect, using known values as 
anchor points (appendix pp 11–12).
For more on the Malaria Atlas 
Project see http://www.map.ox.
ac.uk/
For more on the Malaria 
Indicator Surveys see 
http://www.malariasurveys.org/
For more on the Demographic 
and Health Surveys see 
http://www.dhsprogram.com/
For more on the Multiple 
Indicator Cluster Surveys see 
http://mics.unicef.org/
For the UN Population 
Prospects database  see 
https://esa.un.org/unpd/wpp/
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Continental-level estimates were weighted by the 
population at risk for each country. We produced separate 
estimates of ACT coverage by UN Africa subregion, 
whether or not they were part of the AMFm scheme, 
residence (urban or rural), socioeconomic status (above or 
below country median), endemicity level (hypo endemic, 
mesoendemic, or hyperendemic or holo endemic), and 
health-care provider (public or private). We also produced 
estimates of ACT coverage in children younger than 
5 years with a fever and a negative RDT result.
Meta-analyses of factors influencing individual-level 
coverage
Finally, we used survey datasets with both measured and 
predicted RDT status to assess the association between 
treatment with an ACT for children with fever and 
P falciparum infection and individual, household, and 
community-level factors using random effects meta-
analysis. Urban or rural, wealthy or poor, mean (logit-
transformed) PfPR2–10, household ITN ownership, 
caregiver education (any or none), and child’s age 
(>2 years or ≤2 years) were first included in multivariable 
models for each survey dataset with a random effect at 
the primary sampling unit level. The coefficient and SE 
for each factor from these meta-analyses was then 
entered into a separate meta-regression for each factor, 
with a random effect at the survey level. We ran the same 
models including the health-care provider type, restricted 
to those children who sought treatment, and additionally 
a meta-regression model among all children with fever, 
including only survey-level associations between ACT 
treatment and RDT status and a covariate for before and 
after 2012 to assess the effect of RDT status on ACT 
coverage after policy changes in 2010.
Model validation
We assessed the models for RDT predictions, ACT 
coverage, and ACT availability by withholding a sample 
of the observed values as a testing dataset, and running 
the prediction process on the remaining training dataset. 
We assessed predictive accuracy using both individual-
level hold-out samples and hold-out samples of entire 
surveys. We compared predicted values with observed 
values and assessed the accuracy of predictions using the 
area under the curve (AUC) statistic for RDT status, and 
the root mean square error (RMSE), mean absolute error, 
and mean absolute scaled error for ACT coverage.
To assess how a shorter time period (<14 days) between 
survey and fever date affected our results, we did a 
sensitivity analysis in which the recall period of a fever 
was limited to within the previous 2–7 days. This analysis 
was possible only in a subset of 12 MIS surveys and one 
DHS survey that measured the days since the fever 
started.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
The final dataset included information on 201 704 children 
younger than 5 years from 103 surveys (22 MIS, 61 DHS, 
and 20 MICS) across 33 countries in sub-Saharan Africa 
from 2003–15. RDT results were available for 40 of these 
surveys including 40 261 children (20%; figure 1), and we 
predicted RDT status for the remaining 161 443 children 
(80%). RDT results were far more commonly available in 
recent surveys: 33 (63%) of 52 surveys done from 2010 
onwards collected RDT data, compared with only 
seven (14%) of 51 before 2010.
In the RDT-status prediction model, increasing age, 
decreasing wealth, no household ITN ownership, 
increasing cluster PfPR2–10, rural location, and survey being 
done during the rainy season were all strongly associated 
with a positive RDT (table 1). This model achieved 
relatively good predictive accuracy for individual RDT 
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Figure 1: Frequency plot of surveys included in study, by country and year, with count of febrile children 
younger than 5 years and whether RDT data were collected in survey
103 surveys were included (22 MIS, 61 DHS, and 20 MICS), of which 40 collected RDT data (19 MIS, 20 DHS, and 
one MICS). DHS=Demographic and Health Survey. MICS=Multiple Indicator Cluster Survey. MIS=Malaria Indicator 
Survey. RDT=rapid diagnostic test.
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status, with a mean AUC of 0·78 from 100 independent 15% 
hold-out samples. Survey-level predictive accuracy varied 
from 0·59 to 0·86 (appendix p 7), with a mean of 0·73, 
and ACT coverage using predicted RDT status was 
consistent with ACT coverage using observed RDT status 
(appendix p 6). The GAMM model for predicting missing 
country years achieved an RMSE of 7·4. Further validation 
results are presented in the appendix (p 12).
The continent-wide proportion of children younger 
than 5 years with a fever plus P falciparum infection 
confirmed by RDT who received an ACT was 19·7% 
(95% CI 15·6–24·8) in 2015 (table 2). ACT coverage 
across sub-Saharan Africa increased gradually 
between 2005 and 2015, accelerating slightly 
between 2009 and 2011 (figure 2A). ACT coverage was 
significantly higher in eastern Africa than in central and 
western Africa, and no difference in coverage was seen 
between central and western Africa (figure 2B). Coverage 
was higher in AMFm countries than in non-AMFm 
countries from 2008 to 2015, with a slightly greater 
difference after 2011 (figure 2C). The proportion of 
P falciparum-infected children younger than 5 years with 
fever receiving an ACT in 2015 ranged from a low 
of 0·6% (95% CI 0·0–4·1) in Somalia to a high of 70·2% 
(65·6–74·5) in Uganda (exact country-level data not 
shown; figure 3).
Continent-wide ACT coverage of children with fever 
plus P falciparum infection was similar irrespective of 
location of residence, household wealth, and malaria 
endemicity (figure 4); ACT coverage in 2015 was higher 
in the subgroup of children for whom health care was 
sought than for those for whom health care was not 
sought (table 2). Coverage for children who had treatment 
at public providers was almost twice that of those who 
used private providers in 2015 (figure 4, table 2). 
Continent-wide ACT coverage for children whose RDTs 
were positive or negative was roughly the same between 
2003 and 2012, with coverage appearing to be slightly 
higher for those with positive RDT results after 2012 
(figure 4).
In a meta-analysis of country datasets, children with a 
fever and P falciparum infection were more likely to 
receive an ACT if their caregiver had any education, if 
their household wealth was above the country median, if 
their household owned an ITN, and if they lived in an 
urban area (table 3). Of the children for whom treatment 
was sought, children older than 2 years, whose caregiver 
had any education, whose household owned an ITN, who 
were living in a community with higher mean PfPR2–10, or 
for whom treatment was sought at a public facility were 
more likely to receive an ACT (table 3). Finally, a positive 
RDT status in children with fever was far more likely to 
be associated with receiving an ACT in 2012–15 than it 
was in 2003–11 (OR 1·35, 95% CI 1·15–1·58).
Coefficient 95% CI p value
Age (years)
<1 Ref ·· ··
1–2 1·62 1·49–1·75 <0·0001
2–3 2·36 2·18–2·56 <0·0001
3–4 2·77 2·55–3·02 <0·0001
4–5 2·88 2·64–3·14 <0·0001
Wealth quintile
Poorest Ref ·· ··
Poor 1·06 1·00–1·13 0·0586
Middle 1·05 0·98–1·12 0·1849
Wealthy 0·82 0·76–0·88 <0·0001
Wealthiest 0·44 0·40–0·49 <0·0001
Urban residence 0·69 0·65–0·74 <0·0001
Household owns ≥1 
insecticide-treated net
0·93 0·89–0·98 0·0080
PfPR2–10 2·10 2·06–2·14 <0·0001
Survey done in rainy 
season
1·18 1·12–1·24 <0·0001
Estimates are based on a logistic model of 40 261 children younger than 5 years 
with rapid diagnostic test status. Using these coefficients, rapid diagnostic test 
status was then predicted for 161 443 children. PfPR2–10=mean (logit-transformed) 
Plasmodium falciparum prevalence in children aged 2–10 years.
Table 1: Coefficient values of model predicting rapid diagnostic test 
status for children younger than 5 years
Children <5 years with fever 
and infection who received an ACT
Test positivity
RDT positive 19·7% (15·6–24·8)
RDT negative 16·3% (13·4–19·4)
Residence
Rural 19·7% (15·4–25·4)
Urban 18·9% (9·9–31·3)
Socioeconomic status
Poorer (<median wealth) 18·8% (14·4–24·8)
Wealthier (>median wealth) 21·2% (14·8–29·7)
Endemicity
Hypoendemic 16·9% (8·3–30·6)
Mesoendemic 19·8% (15·9–24·6)
Hyperendemic or holoendemic 19·0% (9·9–35·3)
Treatment seeking
Did seek care 25·9% (20·1–33·4)
Did not seek care 8·3% (5·2–13·0)
Health-care provider
Private 18·7% (11·5–28·3)
Public 30·6% (22·8–41·2)
Estimates are mean (95% CI) and are for children younger than 5 years with a 
fever and an infection (RDT positive), apart from the test positivity data, which is 
for all children younger than 5 years with a fever. Data were calculated excluding 
those countries with a mean Plasmodium falciparum prevalence in children aged 
2–10 years of less than 2%: Botswana, Djibouti, Eritrea, Ethiopia, South Africa, and 
Swaziland. Estimates were adjusted by the population at risk for each stratum.  
ACT=artemisinin-based combination therapy. RDT=rapid diagnostic test.
Table 2: Estimates of proportions of children younger than 5 years with 
a fever and Plasmodium falciparum infection who received an ACT in 
sub-Saharan countries in 2015
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Discussion
In this study we estimated the proportion of children 
younger than 5 years with a fever and P falciparum 
infection confirmed by RDT receiving an ACT by country 
and year for 2003–15 across sub-Saharan Africa. To the 
best of our knowledge, this study is the first to use this 
indicator for assessing the progress of malaria treatment 
in children who need treatment, at the continental and 
country level and by year. Although we documented 
noticeable increases in ACT coverage from 2003 to 2015, 
which correspond with increased investments in ACTs 
and RDTs, coverage remains unacceptably low across 
Africa: over three-quarters (80·3%) of children with 
malaria did not get a potentially life-saving ACT in 2015. 
The two biggest drivers of this coverage gap are poor 
access to and delivery of health services. Only 8·3% of 
people who did not seek care from a health provider 
outside the home received an ACT, and even of those 
who did seek care, only a quarter received an ACT; of 
these individuals, those who sought treatment in the 
public sector were far more likely to receive an ACT than 
those who went to a private health-care provider.
Considerable variation was seen in coverage across 
countries and over time, and a few large countries with low 
coverage—eg, Nigeria—strongly affected regional and 
continental estimates. These low-coverage estimates, and 
especially the low estimates in some large, high-burden 
countries, show that people most in need in highly 
endemic areas are often the least likely to get appropriate 
treatment for malaria. Notably, the greatest improvement 
in coverage was seen mainly in eastern African countries 
that have also shown progress in scaling up ITN coverage,16 
suggesting that higher ACT coverage is linked to overall 
scale-up of malaria interventions. Greater improvement in 
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Figure 2: Proportions of children younger than 5 years with fever and Plasmodium falciparum infection who received an ACT in sub-Saharan Africa, 2003–15
ACT coverage for sub-Saharan Africa (A), stratified by UN subregion (B), and by presence or absence of an AMFm scheme (C). Southern Africa is not included in the 
graph because all countries other than Namibia had a mean P falciparum prevalence in children aged 2–10 years of less than 2%. Namibia was included in central Africa 
because its endemic area is at the same latitude as countries in this region. Dotted lines show 95% CI. ACT=artemisinin-based combination therapy. 
AMFm=Affordable Medicines Facility, malaria.
Figure 3: Proportions of children younger than 5 years with fever and Plasmodium falciparum infection who received an ACT, per country, in 2005, 2010, 
and 2015
Countries with a mean P falciparum prevalence in children aged 2–10 years of less than 2% are in grey. ACT=artemisinin-based combination therapy.
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0 25 50 75 100
ACT coverage (%)
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coverage was also seen in countries supported by AMFm 
funding, although we were unable to determine from this 
analysis whether this effect was directly associated with the 
total amount or type of funding, or some other factor.
Addressing disparities in access to and delivery of 
ACTs is crucial for preventing severe disease and death 
in those most in need, and might also contribute to the 
reduction of transmission when high population 
coverage is reached.2,17 Although in continental-level 
estimates, the CIs for ACT coverage stratified by urban 
or rural residence, wealth, endemicity, and RDT status 
overlapped, in individual-level meta-analyses we found 
Figure 4: Proportions of children younger than 5 years with fever and a Plasmodium falciparum infection in sub-Saharan Africa who received an ACT in 
2003–15, stratified by demographic and clinical variables
ACT coverage stratified by residence type (A), public or private health-care provider (B), positive or negative RDT results (C), malaria endemicity (D), wealth relative 
to median country wealth index (E), and treatment seeking (F). ACT=artemisinin combination therapy. RDT=rapid diagnostic test.
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Summary OR 
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Summary OR 
(95% CI)
p value
Age of child (>2 years vs ≤2 years) 73 1·09 (1·01–1·17) 0·0205 59 1·30 (1·20–1·40) <0·0001
Caregiver’s education (any vs none) 72 1·31 (1·22–1·41) <0·0001 58 1·24 (1·13–1·36) <0·0001
Household wealth 
(above vs below national median wealth index)
73 1·26 (1·16–1·39) <0·0001 59 1·13 (0·99–1·27) 0·0530
Household insecticide-treated net ownership 
(yes vs no)
72 1·21 (1·13–1·29) <0·0001 57 1·16 (1·07–1·27) 0·0005
Area of residence (urban vs rural) 70 1·18 (1·06–1·31) 0·0020 56 1·11 (0·97–1·27) 0·1329
PfPR2–10 73 1·12 (1·02–1·23) 0·0193 59 1·20 (1·08–1·33) 0·0006
Health care (public vs private or other) NA NA NA 54 3·18 (2·67–3·78) <0·0001
Results of meta-analyses of individual survey-dataset-level regressions on ACT coverage for all children with fever and positive RDT results, and in the subgroup of those for 
whom treatment was sought. Surveys were excluded if fewer than five children who participated took an ACT. The number of surveys per parameter varied because for some 
surveys no variability was seen in that parameter. Multiple Indicator Cluster Surveys were excluded from the data of those who did seek treatment because they did not include 
information on where fever treatment was sought. RDT=rapid diagnostic test. ACT=artemisinin-based combination therapy. OR=odds ratio. PfPR2–10=mean (logit-transformed) 
P falciparum prevalence in children aged 2–10 years. NA=not applicable. PfPR2–10=mean (logit-transformed) Plasmodium falciparum prevalence in children aged 2–10 years.
Table 3: Meta-analysis of factors associated with individual-level ACT coverage for children younger than 5 years with a fever and Plasmodium falciparum 
infection, in all children and those for whom treatment was sought
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that poorer children living in rural areas with fever and a 
P falciparum infection were significantly less likely to 
receive an ACT than children who lived in urban areas 
and had a household wealth index above the national 
median, as were those whose caregiver had no education 
and whose household did not own an ITN. These 
variables—area of residence, household wealth, 
education, and ITN ownership—are all proxies for access 
to health services and influence the seeking of treatment 
for fever. Estimates of the proportion of children younger 
than 5 years with fever taken for any care are between 56% 
and 69% across sub-Saharan Africa.18 Of children for 
whom treatment was sought, urban residence and wealth 
were not significant predictors of ACT treatment. 
Improving access to care and provision of ACT treatment 
in poor, rural populations19 is crucial for sustaining 
efforts to control malaria and progressing towards 
elimination. Our finding that 8·3% of children received 
an ACT even when their caregivers did not report seeking 
treatment outside the home was somewhat surprising, 
but largely driven by data from countries with very high 
overall ACT coverage (eg, Uganda) or where mass drug 
administration activities have recently been done 
(eg, Zambia). In these cases, there might be large 
quantities of circulating ACTs in the community.
Our findings are consistent with those of other studies 
that have explored the combination of patient and provider 
factors that influence ACT coverage. Galactionova and 
colleagues20 documented large differences between the 
factors that most influenced effectiveness of malaria case 
management across sub-Saharan Africa, including access 
to a health-care provider, provider compliance and patient 
adherence with front-line antimalarial policy, and drug 
quality. Consistent with our analysis, they found that in 
many countries effective coverage was low because of 
poor access to heath-care providers, but in several 
countries with high access to providers, effective coverage 
was low because of poor provider compliance with 
national ACT policy.20 Littrell and colleagues21 similarly 
found low effective coverage in Zambia due to a 
combination of low treatment-seeking behaviour by 
patients and low rates of diagnostic confirmation at health 
facilities.21 Several similar studies have documented 
individual provider barriers, including frequent stockouts22 
and low availability of diagnostics, and individual patient 
barriers such as distance to formal facilities, lack of 
financial resources, and low maternal education.23,24
The private sector continues to lag behind the public 
sector at scaling up RDTs and ACTs, showing a huge 
unmet need in treatment because in much of sub-
Saharan Africa, rural, poor households receive care 
primarily through the private sector.18,24–26 We found 
substantially lower coverage for children who sought 
care at private providers than for those who visited public 
providers in both continent-level predictions and 
individual-level regression analyses, which is consistent 
with previous research.27 Of children with fever and a 
P falciparum infection who sought treatment in the 
private sector, less than a fifth received an ACT in 2015. 
Substantial efforts have been made to increase the 
availability of ACTs through the private sector in Africa 
through initiatives like the AMFm, with notable 
improvements in some areas,28–30 but the scarce access to 
ACTs through the private sector remains an important 
impediment to malaria control and burden reduction, 
especially for people living in rural areas, who have 
below-average household wealth.
The traditional indicator of ACT coverage, measured in 
all children with fever, does not allow for monitoring and 
assessment of appropriate treatment for those who need 
it. Instead, the improved indicator of ACT coverage that 
includes RDT status allows assessment of not only the 
proportion of children in need who received ACT, but 
also the proportion without a malaria parasite infection 
that inappropriately received ACT. We found only minor 
differences in ACT coverage between children with a 
malarial fever and those with a non-malarial fever, which 
points to considerable inefficiencies in ACT allocation. 
This result is not entirely surprising because RDTs were 
not widely scaled up across most of Africa until after 2010, 
and most suspected cases were treated on the basis of 
clinical diagnosis only. After 2012, our results show that 
malaria parasite-infected children with fever were more 
likely to receive an ACT than children with a fever but no 
malaria infection, suggesting improvements in 
appropriate treatment. Although we did not examine 
diagnostic coverage in this study, our results suggest that 
improvements are happening; however, on a continental 
scale, scale-up of diagnostics might not yet be having a 
marked effect on prescription practices and appropriate 
treatment.
The approach used in our study has some limitations. 
First, because of the time lag between measurement of 
RDT status and treatment for fever, a positive RDT result 
at the time of survey does not necessarily indicate that a 
child had a malaria infection during their recent fever 
episode and, if they were tested at a clinic, that they 
would have had a positive RDT result. Although all fevers 
combined with P falciparum infection warrant treatment 
with an ACT, some children who either were not yet 
infected at the time of their fever or had very low-density 
infections might have had negative RDT test results or 
been clinically diagnosed with a different condition. 
Similarly, a negative RDT at the time of survey does not 
rule out a P falciparum infection in recent weeks, 
especially given the relatively low sensitivity of particular 
RDTs in field settings31 and the possibility of hrp2 
deletion in some parasites.32 Third, although predictive 
models showed good accuracy, we cannot be certain of 
accurately ascertaining each child’s RDT status. However, 
children predicted to be RDT positive were more likely to 
be poor, have no household ITN, and live in high-
prevalence and rural areas than those who were predicted 
to be RDT negative, all of which suggest greater need for 
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ACT treatment for fever. Fourth, only a few surveys 
include the number of days since the fever was reported, 
which would have allowed us to remove children with 
very short or long times since fever, and reduced the 
potential for recall bias. Using those surveys that 
included this indicator, we did a sensitivity analysis that 
showed consistency in estimating ACT coverage in 
children with a fever and P falciparum infection using a 
shorter, 1 week  period of recall. In a previous study,33 we 
documented high accuracy of caregiver recall for ACT 
treatment within the previous 2 weeks from a household 
survey in Zambia, but recall bias could be greater in 
other settings. Fifth, our predictions were limited by the 
relatively small sample sizes in many of the surveys, 
because these surveys are not typically powered to obtain 
representative estimates for children with fever, and also 
might not capture subnational heterogeneity in malaria 
transmission risk. Because the relatively small sample 
sizes probably influenced our ability to produce precise 
estimates, we incorporated multiple levels of uncertainty 
and reflect these in our estimates. Finally, the indicator of 
ACT treatment for fever and a positive RDT result is only 
a proxy measure for appropriate treatment for 
uncomplicated malaria. Although the inclusion of 
infection status is a notable improvement, appropriate 
treatment involves additional steps such as ensuring 
correct dosage and patient adherence, and exploring 
alternative causes of fever, which are not captured by this 
indicator. As countries move to improve data collection 
through the health system, robust routine collection of 
test results and treatment outcomes for fever is crucial 
for monitoring and evaluation of malaria case 
management; periodic health facility surveys that include 
exit interviews for patients seeking care for fever could 
provide an additional important datapoint to complement 
routine and household survey data.
We document, for the first time to our knowledge, 
continental and country-specific trends in ACT coverage 
in children who need an ACT (ie, those who have fever 
and a P falciparum parasite infection) over the past 
decade of scale-up, and show that even after the large 
investments in malaria prevention, diagnostic testing, 
and treatment over the past decade, ACTs are not 
reaching most children with malaria who need 
treatment. In addition to investing in new technologies 
and tools, malaria programmes need to ensure that 
individuals with malaria receive treatment through 
greater access to health care and consistent availability 
and provision of ACTs in areas of greatest need. 
Improved care in all health sectors, including continued 
scale-up of integrated community case management, 
will be essential for improving access to ACTs, especially 
for rural households with low incomes and low access to 
health services. This research shows the large gap in 
appropriate treatment of uncomplicated malaria and the 
potential to increase the positive impact of malaria 
control and elimination programmes.
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